Intersex Research Paper

Les êtres humains font et refont le sexe, le genre et la sexualité, avec des implications à la fois sociales, politiques, culturelles, juridiques et économiques. En même temps, nul ne peut refaire le monde ni se refaire soi-même... more

Les êtres humains font et refont le sexe, le genre et la sexualité, avec des implications à la fois sociales, politiques, culturelles, juridiques et économiques. En même temps, nul ne peut refaire le monde ni se refaire soi-même exactement comme on l’entend. Les relations, les discours et les institutions historiques, normatives, disciplinaires pèsent sur ce que Janik
Bastien Charlebois (2014) appelle « la matrice sexe/genre/sexualité ». Cette matrice normalisatrice structure les relations au quotidien, tout comme les savoirs, y compris ceux produits au sein de l’Université. Contestée, elle incarne néanmoins le sens commun. Ainsi, dans l’Europe contemporaine, il semble évident à la majorité qu’il y a deux sexes, que seules l’hétérosexualité ainsi que certaines formes d’homosexualité sont possibles, que le genre est distinct du sexe et qu’ils sont tous deux stables, depuis la naissance. Ces idées façonnent nos droits et nos institutions politiques, les médias et la culture populaire, nos vies quotidiennes et les mouvements sociaux.
Les dernières décennies ont vu de nouvelles voix venir contester ces idées reçues. Les sciences sociales pourraient s’inspirer des efforts riches et divers de ces chercheurs venant des marges, ainsi que des analyses qui sont en dialogue avec leurs contributions. En particulier, ces recherches fournissent de nouvelles généalogies du pouvoir institutionnalisé, genré et sexué, depuis les colonialismes du xixe siècle jusqu’à la période contemporaine. En outre, d’une manière inévitablement partielle, fragmentée, parfois contradictoire, elles nous aident à imaginer des relations sociales au-delà des pratiques et des normes, souvent étroites, du présent.

1. Lee PA, Houk CP, Ahmed SF, Hughes IA, Houk A, Hughes IA. Consensus statement on management of intersex disorders. Pediatrics. 2006;118(2):e488–500.[PubMed]

2. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2013;21(3):245–91.[PubMed]

3. Intersex Society of North America (ISNA) What is Intersex? 2008. [Accessed June 1, 2016]. Available at: http://www.isna.org/faq/what_is_intersex.

4. Crain DA, Janssen SJ, Edwards TM, et al. Female reproductive disorders: the roles of endocrine-disrupting compounds and development timing. Fertil Steril. 2008;90(4):911–40.[PMC free article][PubMed]

5. Fowler PA, Bellingham M, Sinclair KD, et al. Impact of endocrine-disrupting compounds (EDCs) on female reproductive health. Mol Cell Endocrinol. 2012;355:231–9.[PubMed]

6. Earl-Gray L, Wilson VS, Stoker T, et al. Adverse effects of environmental antiandrogens and androgens on reproductive development in mammals. Int J Androl. 2006;29(1):96–104.[PubMed]

7. Zoeller RT, Brown TR, Doan LL, et al. Endocrine-disrupting chemicals and public health protection: a statement of principles from The Endocrine Society. Endocrinology. 2012;153(9):4097–110.[PMC free article][PubMed]

8. Hamlin HJ, Guillette LJ., Jr Birth defects in wildlife: the role of environmental contaminants as inducers of reproductive and developmental dysfunctions. Syst Biol Reprod Med. 2010;56(2):113–21.[PubMed]

9. Niemuth NJ, Klapper RD. Emerging wastewater contaminant metformin causes intersex and reduced fecundity in fish. Chemosphere. 2015;135:38–45.[PubMed]

10. Accord Alliance (n.d.). Intersex. [Accessed June 1, 2016]. Available at http://www.accordalliance.org/glossary/intersex/

11. Lilford RJ, Dear PR. The intersex baby. Br J Hosp Med (Lond) 1987;37(1):28–30.[PubMed]

12. World Health Organization (WHO) Gender and Genetics: Genetic Components of Sex and Gender. [Accessed July 27, 2015]. Available at: http://www.who.int/genomics/gender/en/index1.html.

13. Ahmed SF, Dobbie R, Finlayson AR, et al. Prevalence of hypospadias and other genital anomalies among singleton births, 1988–1997, in Scotland. Arch Dis Child Fetal Neonatal Ed. 2004;89:F149–51.[PMC free article][PubMed]

14. Gaspari L, Paris F, Jandel C, et al. Prenatal environmental risk factors for genital malformations in a population of 1442 French male newborns: a nested case–control study. Hum Reprod. 2011;26(11):3155–62.[PubMed]

15. Svechnikov K, Stukenborg JB, Savchuck I, Söder O. Similar causes of various reproductive disorders in early life. Asian J Androl. 2014;16:50–9.[PMC free article][PubMed]

16. Sharpe R. Hormones and testis development and the possible adverse effects of environmental chemicals. Toxicol Lett. 2001;120:221–32.[PubMed]

17. Kavlock RJ, Daston GP, DeRosa C, et al. Research needs for the assessment of health and environmental effects of endocrine disruptor: a report of the US EPA-sponsored workshop. Environ Health Perspect. 1996;104(Suppl 4):715–40.[PMC free article][PubMed]

18. Newbold RR. Developmental exposure to endocrine-disrupting chemicals programs for reproductive tract alterations and obesity in later years. Am J Clin Nutr. 2011;94(6 Supple):1939S–42S.[PMC free article][PubMed]

19. Acerini CL, Hughes IA. Endocrine disrupting chemicals: a new and emerging public health problem? Arch Dis Child. 2006;91:633–8.[PMC free article][PubMed]

20. Laino L, Majore S, Preziosi N, et al. Disorders of sex development: a genetic study of patients in a multidisciplinary clinic. Endocr Connect. 2014;3(4):180–92.[PMC free article][PubMed]

21. World Health Organization (WHO) Gender and Genetics: Genetic Components of Sex and Gender. [Accessed July 27, 2015]. Available at: http://www.who.int/genomics/gender/en/index1.html.

22. National Institute of Health (NIH) NIH FY 2016–2020 Strategic plan to advance research on the health and well-bring of sexual and gender minorities. [Accessed October 11, 2015]. Available at: http://edi.nih.gov/sites/default/files/EDI_Public_files/sgm-strategic-plan.pdf.

23. Hughes IA. Disorders of sex development: a new definition and classification. Best Pract Res Clin Endocrinol Metab. 2008;22(1):119–34.[PubMed]

24. Öcal B, Berberoğlu M, Siklar Z, et al. Clinical review of 95 patients with 46, XX disorders of sex development based on the New Chicago classification. J Pediatr Adolesc Gyneco. 2015;28(1):6–11.[PubMed]

25. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95(9):4133–60.[PMC free article][PubMed]

26. Frisén L, Nordenström A, Falhammar H, et al. Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21 A2 deficiency. J Clin Endocrinol Metab. 2009;94(9):3432–9.[PubMed]

27. Erdoğan S, Kara C, Uçaktürk A, Aydin M. Etiological classification and clinical assessment of children and adolescents with disorders of sex development. J Clin Res Pediatr Endocrinol. 2011;3(2):77–83.[PMC free article][PubMed]

28. Kousta E, Papathanasiou A, Skordis N. Sex determination and disorders of sex development according to the revised nomenclature and classification in 46, XX individuals. Hormones. 2010;9(3):218–31.[PubMed]

29. Frisén L, Nordenström A, Falhammar H, et al. Gender role behaviour, sexuality, and psychosocial adaptation in women and congenital adrenal hyperplasia due to CYP21 A2 deficiency. J Clin Endocrinol Metab. 2009;94(9):3432–9.[PubMed]

30. Liang HY, Chang HL, Chen CY, Chang PY, Lo FS, Lee LW. Psychiatric manifestation in young females with congenital adrenal hyperplasia in Taiwan. Chang Gung Med J. 2008;31:66–73.[PubMed]

31. Blackless M, Charuvastra A, Derryck A, Fausto-Sterling A, Lauzanne K, Lee E. How sexually dimorphic are we? Review and synthesis. Am J Hum Biol. 2000;12:151–66.[PubMed]

32. NTP (National Toxicology Program) Endocrine Disruptors Low-Dose Peer Review. Research Triangle Park: NTP; 2003. [Accessed March, 22, 2016]. Final report of the endocrine disruptors low-dose peer review panel. Available at: http://ntp.niehs.nih.gov/ntp/htdocs/liason/lowdosepeerfinalrpt.pdf.

33. Vom Saal FS, Timms BG, Montano MM, et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci U S A. 1997;94:2056–62.[PMC free article][PubMed]

34. Palanza P, Howdeshell KL, Parmigiani S, vom Saal FS. Exposure to a low dose of Bisphenol A during fetal life or in adulthood alters material behavior in mice. Env Health Perspect. 2002;110(Suppl 3):415–22.[PMC free article][PubMed]

35. Zoeller RT, Brown TR, Doan LL, et al. Endocrine-disrupting chemicals and public health protection: a statement of principles from The Endocrine Society. Endocrinology. 2012;153(9):4097–110.[PMC free article][PubMed]

36. Ostby J, Monosson E, Kelce WR, Gray LE., Jr Environmental antiandrogens: low doses of the fungicide vinclozolin alter sexual differentiation of the male rate. Toxicol Ind Health. 1999;15:48–64.[PubMed]

37. Prener A, Engholm G, Jensen OM. Genital anomalies and risk for testicular cancer in Danish men. Epidemiology. 1996;7(1):14–9.[PubMed]

38. Wang MH, Baskin LS. Endocrine disruptors, genital development, and hypospadias. J Androl. 2008;29(5):499–505.[PubMed]

39. Newbold RR. Developmental exposure to endocrine-disrupting chemicals programs for reproductive tract alterations and obesity in later years. Am J Clin Nutr. 2011;94(6 supple):1939S–42S.[PMC free article][PubMed]

40. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects: opinion. Hum Reprod. 2001;16(5):972–8.[PubMed]

41. Bartman T, Hove J. Mechanics and function in heart morphogenesis. Dev Dyn. 2005;233:373–81.[PubMed]

42. Anderson RH, Webb S, Brown NA, Lamers W, Moorman A. Development of the heart: (3) formations of the ventricular outflow tracts, arterial valves and intrapericardial arterial trunks. Heart. 2003;9(9):1110–8.[PMC free article][PubMed]

43. Costa VM, Carvalho F, Duarte JA, de Lourdes Bastos M, Remião F. The heart as a target for xenobiotic toxicity: the cardiac susceptibility to oxidative stress. Chem Res Toxicol. 2013;26:1285–311.[PubMed]

44. Korones S. Anatomic aspects of fetal development. Glob Libr Womens Med. 2008:1–22. doi: 10.3843/GLOWM.10102.[Cross Ref]

45. Rauhut-Klaban M, Bruska M, Woźniak W. Early trabeculation and close of the interventricular foramen in staged human embryos. Folia Morphol. 2008;67(1):13–8.[PubMed]

46. Anderson RH, Webb S, Brown NA, Lamers W, Moorman A. Development of the heart: (3) formations of the ventricular outflow tracts, arterial valves and intrapericardial arterial trunks. Heart. 2003;9(9):1110–8.[PMC free article][PubMed]

47. Artamonova GV, Shapovlova EB, Maksimov SA, Skripchenko AE, Ogarkov Mlu. The environment as a risk factor for coronary heart disease in urbanized regions with developed chemical industry. Kardiologiia. 2012;52(10):86–90.[PubMed]

48. Thornton PS, Satin-Smith MS, Glaser HK, et al. Familial hyperinsulism with apparent autosomal dominant inheritance: clinical and genetic differences from the autosomal recessive variant. J Pediatr. 1998;132(1):9–14.[PubMed]

49. Costa VM, Carvalho F, Duarte JA, de Lourdes Bastos M, Remião F. The heart as a target for xenobiotic toxicity: the cardiac susceptibility to oxidative stress. Chem Res Toxicol. 2013;26:1285–311.[PubMed]

50. Gorini F, Chiappi E, Gargani L, Picano E. Potential effects of environmental chemical contamination in congenital heart disease. Pediatr Cardiol. 2014;35:559–68.[PubMed]

51. Gorlin RJ, Kantaputra P, Aughton DJ, Julliken JB. Marked female predilection in some syndromes associate with facial hemangiomas. Am J Med Genet. 1994;52:130–5.[PubMed]

52. Ermito S, Dinatale A, Carrara S, Cavaliere A, Imbruglia L, Recupero S. Prenatal diagnosis of limb abnormalities: role of fetal ultrasonography. J Prenat Med. 2009;3(2):18–22.[PMC free article][PubMed]

53. Lingaiah K, Parshwanath BA, Mysore SR, Krishnamurthy B, Ramachandra NB. A rare case of congential heart disease with ambiguous genitalia. Indian J Hum Genet. 2010;16(3):166–8.[PMC free article][PubMed]

54. Low Y, Deshpande AV, Hutson JM. Lethal comorbidity with genital anomaly in the infant. J Pediatr Urol. 2006;2(6):534–8.[PubMed]

55. Bondy CA, Ceniceros I, Van PL, Bakalov VK, Rosing DR. Prolonged rate-corrected QT interval and other electrocardiogram abnormalities in girls with Turner Syndrome. Pediatrics. 2006;118(4):e1220–5.[PubMed]

56. Lippe B. Turner syndrome. Endocrinol Metab Clin North Am. 1991;20:121–52.[PubMed]

57. Davenport ML. Approach to the patient with Turner Syndrome. J Clin Endocrinol Metab. 2010;95:1487–95.[PubMed]

58. Stenberg AE, Nylen O, Windh M, Hultcrantz M. Otological problems in children with Turner’s syndrome. Hear Res. 1998;124(1–2):85–90.[PubMed]

59. Bondy CA, Ceniceros I, Van PL, Bakalov VK, Rosing DR. Prolonged rate-corrected QT interval and other electrocardiogram abnormalities in girls with Turner Syndrome. Pediatrics. 2006;118(4):e1220–5.[PubMed]

60. Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in turner syndrome. J Clin Endocrinol Metab. 2008;93(2):344–51.[PubMed]

61.

0 thoughts on “Intersex Research Paper”

    -->

Leave a Comment

Your email address will not be published. Required fields are marked *